

Skinny Labeling Post-GSK v. Teva: How the Decision Will Inform Biosimilar Carve-Outs

Location

Webinar

Date & Time

Start Date: 06/22/2021

Start Time: 1:00 pm

End Time: 2:00 pm EDT

Blake Coblentz will join a panel discussing skinny labeling on a pharmaceutical product. At the time of press, the Federal Circuit vacated its prior ruling finding induced infringement based on so-called skinny labeling on a pharmaceutical product in *GSK v. Teva* (Fed. Cir. Feb. 9, 2021). As we await a final decision, this panel will provide strategies and tactics in view of the decision, including:

- Reevaluating claim and label language for optimal drafting
- Analyzing what types of evidence should be used to prove infringement
- Understanding second medical use patents and carve-out strategies
 - Clarifying the patentability of further medical use inventions
- Outlining the implications of the Federal Circuit decision striking down labeling carve-outs
- Determining whether post-filing evidence is admissible to show insufficient disclosure of further medical use
- Balancing competing interests in promoting innovation v. permitting generic drugs

Sponsor

American Conference Institute

Share Post

ATTORNEYS



W. Blake Coblentz
Co-Chair, Hatch-Waxman & Biologics
Vice Chair, Intellectual Property

wcoblentz@cozen.com

(202) 912-4837

RELATED PRACTICES

Hatch-Waxman & Biologics
Intellectual Property

